Alliqua Biomedical
Alliqua prices $30m offering
Alliqua Biomedical (NSDQ:ALQA) today said it priced a public stock offering worth $30 million for its hydrogel wound care technology.
The Langhorne, Pa.-based company said it plan to offer nearly 6.9 million shares at $4.55 apiece.
Year in review: CEOs chime in on 2014
As 2014 draws to a close, MassDevice.com asked several medical device company CEOs for their takes on 2014 and what they’re looking for in 2015.
We wanted to get their views on the major trends seen in medtech this year, including the red-hot M&A and IPO scenes, the medical device tax, the regulatory environment in the U.S., and more.
Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson
Alliqua Biomedical (NSDQ:ALQA) CEO Dave Johnson hasn’t been at the helm very long, but the company has seen a major turnaround during his time.
Alliqua board members and executives drive recent financing round
Wound dressing device maker Alliqua closed a $3 million equity financing round, largely backed by an insider group of board members and executives.
Alliqua drummed up the cash over the course of 3 months through sale of common stock, according to a company statement. Accredited investors paid 81¢ per share for equity, coupled with a warrant to purchase an additional share at 97¢ apiece.
Medtronic home healthcare system cuts costs: Study | Research roundup
Medtronic Inc. (NYSE:MDT) said the results of a clinical trial for its new remote monitoring network indicate that the system reduces healthcare costs.
The study showed that monitoring of implantable cardiac device patients with the Medtronic’s CareLink network and CareAlert notification system cuts down on healthcare utilization costs when compared to in-office follow-up appointments, according to the company.
HepaLife hopes for new life as Alliqua
HepaLife Technologies Inc. (OTC:HPLF) is now Alliqua Inc.
